The wintry weekend brought a pseudo-hurricane over Lake Michigan, and skyward pillars of light that aren't really what they ...

Mesoblast says FDA feedback supports filing plans for its cell therapy to treat chronic back pain, showing reduced pain and lower opioid use in a late-stage trial.

A downtrend has been apparent in Mesoblast Limited (MESO) lately. While the stock has lost 10.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

We’re no strangers to the concept of superfoods. (C’mon, it’s 2019.) But the now-familiar (and somewhat overhyped) food fad is about to resurface in a new way, and it might actually be better for your ...

Mesoblast Limited’s MESO shares surged 78.6% on Mar 26, after an encouraging regulatory update from the FDA for its lead product candidate, remestemcel-L, which is being developed for the treatment of ...

Mesoblast's remestemcel (Ryoncil) is FDA-approved for steroid-refractory acute graft-versus-host disease in patients two months and older, marking a significant milestone for MSC therapies in the US.

Honey-glazed duck with Brussels sprouts, figs soaked in brandy, and potato gratin. Drawing upon the cuisines of France, Italy, Spain, Greece, and North Africa, Meso shows Westchester just how ...